These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10580736)

  • 1. Using pharmacodynamic and pharmacokinetic surrogate markers in clinical practice: optimizing antimicrobial therapy in respiratory-tract infections.
    Nicolau DP
    Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S16-20. PubMed ID: 10580736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients.
    Schentag JJ
    Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S21-4. PubMed ID: 10580737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
    Andes D; Anon J; Jacobs MR; Craig WA
    Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract.
    Wise R; Honeybourne D
    Eur Respir J; 1999 Jul; 14(1):221-9. PubMed ID: 10489856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics of antimicrobial therapy.
    Paladino JA
    Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S25-8. PubMed ID: 10580738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections.
    Kohno S; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Fujita J; Tanigawara Y
    J Infect Chemother; 2013 Jun; 19(3):486-94. PubMed ID: 23525983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
    Parra-Ruiz J; Hernández-Quero J
    Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H; Carbon C
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.
    Drusano GL; Craig WA
    J Chemother; 1997 May; 9 Suppl 3():38-44. PubMed ID: 9248979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin.
    Drusano G
    Clin Microbiol Infect; 2001; 7 Suppl 3():24-9. PubMed ID: 11523559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
    Jones RN; Pfaller MA
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.